10x Genomics, Inc. TXG
We take great care to ensure that the data presented and summarized in this overview for 10x Genomics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TXG
View all-
Vanguard Group Inc Valley Forge, PA9.1MShares$228 Million0.01% of portfolio
-
Baillie Gifford & CO7.42MShares$186 Million0.22% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.28MShares$157 Million1.68% of portfolio
-
Black Rock Inc. New York, NY6.01MShares$150 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.16MShares$129 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.66MShares$91.5 Million0.02% of portfolio
-
Nikko Asset Management Americas, Inc.3.62MShares$90.6 Million1.36% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.62MShares$90.6 Million0.09% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.38MShares$84.6 Million0.37% of portfolio
-
Brown Capital Management LLC Baltimore, MD2.67MShares$66.9 Million1.8% of portfolio
Latest Institutional Activity in TXG
Top Purchases
Top Sells
About TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Insider Transactions at TXG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 21
2024
|
Justin J. Mc Anear Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,312
+26.41%
|
-
|
Mar 21
2024
|
Benjamin J. Hindson |
BUY
Grant, award, or other acquisition
|
Direct |
71,083
+16.72%
|
-
|
Mar 21
2024
|
Serge Saxonov Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
88,854
+9.04%
|
-
|
Mar 14
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,086
-0.13%
|
-
|
Mar 04
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,660
-0.55%
|
$205,040
$44.0 P/Share
|
Feb 22
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,821
-0.33%
|
$129,766
$46.34 P/Share
|
Feb 22
2024
|
Justin J. Mc Anear Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,865
-1.92%
|
$85,790
$46.34 P/Share
|
Feb 22
2024
|
Benjamin J. Hindson |
SELL
Open market or private sale
|
Direct |
2,613
-0.91%
|
$120,198
$46.34 P/Share
|
Feb 15
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.29%
|
$245,000
$49.01 P/Share
|
Feb 09
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.12%
|
$49,000
$49.53 P/Share
|
Jan 16
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,000
-0.23%
|
$180,000
$45.38 P/Share
|
Dec 28
2023
|
Benjamin J. Hindson |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+2.83%
|
$91,674
$11.48 P/Share
|
Dec 27
2023
|
Serge Saxonov Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,935
+1.71%
|
$14,935
$1.2 P/Share
|
Dec 14
2023
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,000
-0.12%
|
$108,000
$54.77 P/Share
|
Nov 24
2023
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,723
-0.44%
|
$160,089
$43.72 P/Share
|
Nov 22
2023
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,757
-0.44%
|
$161,551
$43.34 P/Share
|
Nov 22
2023
|
Justin J. Mc Anear Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,679
-1.7%
|
$72,197
$43.34 P/Share
|
Nov 22
2023
|
Benjamin J. Hindson |
SELL
Open market or private sale
|
Direct |
3,449
-1.23%
|
$148,307
$43.34 P/Share
|
Nov 22
2023
|
James Wilbur Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,464
-3.99%
|
$148,952
$43.34 P/Share
|
Nov 20
2023
|
James Wilbur Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
14,718
-14.5%
|
$618,156
$42.09 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 224K shares |
---|---|
Exercise of conversion of derivative security | 65K shares |
Open market or private sale | 163K shares |
---|---|
Bona fide gift | 4.9K shares |